Sensorion reports six-month Audiogene trial results for gene therapy

​Sensorion has reported a six-month update from the Audiogene Phase I/II clinical trial’s cohort 2 assessing SENS-501, its gene therapy candidate for otoferlin-mediated congenital deafness.

The post Sensorion reports six-month Audiogene trial results for gene therapy appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.